# US 2012/0253023 A1 · Hybrid polypeptides with selectable properties

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253023 A1
- Document ID: US20120253023A1
- Status: Published application
- Kind: A1
- Application number: 13/323,608
- Filed: 2011-12-12
- Published: 2012-10-04
- Earliest claimed: 2004-02-11
- Assignees: Amylin Pharmaceuticals, Inc.
- Inventors: Odile Esther LEVY; Michael R. Hanley; Carolyn M. Jodka; Diana Y. Lewis; Christopher J. Soares; Soumitra S. Ghosh; Lawrence J. D'Souza; David G. Parkes; Christine M. Mack
- Web page: https://patentgrep.com/patent/US20120253023A1

## CPC

- C07K 14/605: Glucagons
- C07K 5/1013: {the side chain containing O or S as heteroatoms, e.g. Cys, Ser}
- C07K 5/1024: {with the first amino acid being heterocyclic}
- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- C07K 14/58: Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A hybrid polypeptide exhibiting at least one hormonal activity, said hybrid polypeptide comprising a first bio-active peptide hormone module covalently linked to a second bio-active peptide hormone module; wherein:
the bio-active peptide hormone modules are independently selected from the group consisting of: component peptide hormones, fragments of component peptide hormones that exhibit at least one hormonal activity of the component peptide hormones, analogs and derivatives of component peptide hormones that exhibit at least one hormonal activity of the component peptide hormones, fragments of analogs and derivatives of component peptide hormones that exhibit at least one hormonal activity of the component peptide hormones, and peptidic enhancers;
the component peptide hormones are independently selected from at least two of the group consisting of: amylin, PYY, and exendin-4;
the peptidic enhancers are independently selected from the group consisting of: structural motifs of component peptide hormones that impart a desired chemical stability, conformational stability, metabolic stability, bioavailability, organ/tissue targeting, receptor interaction, protease inhibition, plasma protein binding, or other pharmacokinetic characteristic to the hybrid polypeptide, and structural motifs of analogs or derivatives of component peptide hormones that impart a desired chemical stability, conformational stability, metabolic stability, bioavailability, organ/tissue targeting, receptor interaction, protease inhibition, plasma protein binding, or other pharmacokinetic characteristic to the hybrid polypeptide; and
wherein at least one of the bio-active peptide hormone modules exhibits at least one hormonal activity of a component peptide hormone.

### Claim 22 (depends on 21)

The hybrid polypeptide of claim 21, wherein the peptidic enhancers are independently selected from the group consisting of amylin(32-37), amylin(33-37), amylin(34-37), amylin(35-37), amylin(36-37), amylin(37), PYY(25-36), PYY(26-36), PYY(27-36), PYY(28-36), PYY(29-36), PYY(30-36), PYY(31-36), PYY(32-36), PYY(25-35), PYY(26-35), PYY(27-35), PYY(28-35), PYY(29-35), PYY(30-35), PYY(31-35), PYY(32-35), exendin-4(31-39), exendin-4(32-39), exendin-4(33-39), exendin-4(34-39), exendin-4(35-39), exendin-4(36-39), exendin-4(37-39), exendin-4(38-39), exendin-4(39), and analogs thereof.

### Claim 23 (depends on 21)

The hybrid polypeptide of claim 21, wherein the first bio-active peptide hormone module is located at the C-terminal end of the hybrid polypeptide.

### Claim 24 (depends on 21)

The hybrid polypeptide of claim 21, wherein the first bio-active peptide hormone module is located at the N-terminal end of the hybrid polypeptide.

### Claim 25 (depends on 21)

The hybrid polypeptide of claim 21, wherein the hybrid polypeptide comprises bio-active peptide hormone module combinations selected from the group consisting of: exendin-4/PYY, PYY/exendin-4, exendin/amylin, amylin/exendin, amylin/PYY, and PYY/amylin bio-active peptide hormone modules.

### Claim 26 (depends on 24)

A hybrid polypeptide of claim 24, wherein the component peptide hormone of the first bio-active peptide hormone module comprises an exendin-4 and the component peptide hormone of the second bio-active peptide hormone module comprises an amylin.

### Claim 27 (depends on 26)

The hybrid polypeptide of claim 26, wherein the first bio-active peptide hormone module exhibits at least one hormonal activity of exendin-4 and the second bio-active peptide hormone module exhibits at least one hormonal activity of amylin.

### Claim 28 (depends on 27)

The hybrid polypeptide of claim 27, wherein the first bio-active peptide hormone module exhibits stimulating insulin secretion activity and the second bio-active peptide hormone module exhibits reducing body weight activity.

### Claim 29 (depends on 26)

The hybrid polypeptide of claim 26, wherein the first bio-active peptide hormone module comprises a peptide selected from the group consisting of exendin-4, exendin-4 fragments that exhibit at least one hormonal activity of exendin-4, analogs and derivatives of exendin-4 that exhibit at least one hormonal activity of exendin-4, and fragments of analogs and derivatives of exendin-4 that exhibit at least one hormonal activity of exendin-4.

### Claim 30 (depends on 29)

The hybrid polypeptide of claim 29, wherein the first bio-active peptide hormone module comprises exendin-4, a bio-active analog of exendin-4 or a bio-active fragment of exendin-4.

### Claim 31 (depends on 30)

The hybrid polypeptide of claim 30, wherein the first bio-active peptide hormone module has at least 50% amino acid sequence identity to exendin-4.

### Claim 32 (depends on 31)

The hybrid polypeptide of claim 31, wherein the first bio-active peptide hormone module comprises a peptide selected from the group consisting of exendin-4, 14Leu 25Phe-exendin-4, 5Ala14Leu25Phe-exendin-4, 14Leu 22Ala 25Phe-exendin-4, exendin(7-15), 2Ser-exendin(7-15), exendin-4(1-27), exendin(1-28), exendin-4(1-29), exendin-4(1-30), 14Leu 25Phe-exendin-4(1-27), 5Ala 14Leu 25Phe-exendin-4(1-27), 14Leu 22Ala 25Phe-exendin-4(1-27), 14Leu 25Phe-exendin-4(1-28); 5Ala 14Leu 25Phe-exendin-4(1-28), and 14Leu-exendin-4(1-28).

### Claim 33 (depends on 26)

The hybrid polypeptide of claim 26, wherein the second bio-active peptide hormone module comprises a peptide selected from the group consisting of amylin, amylin fragments that exhibit at least one hormonal activity of amylin, analogs and derivatives of amylin that exhibit at least one hormonal activity of amylin, and fragments of analogs and derivatives of amylin that exhibit at least one hormonal activity of amylin.

### Claim 34 (depends on 33)

The hybrid polypeptide of claim 33, wherein the second bio-active peptide hormone module comprises amylin, a bio-active analog of amylin or a bio-active fragment of amylin.

### Claim 35 (depends on 34)

The hybrid polypeptide of claim 34, wherein the second bio-active peptide hormone module has at least 50% amino acid sequence identity to its human amylin.

### Claim 36 (depends on 35)

The hybrid polypeptide of claim 35, wherein the second bio-active peptide hormone module comprises a peptide selected from the group consisting of amylin, 2829 Pro-h-amylin, amylin(1-7), 2,7Ala-amylin(1-7), sCT(8-10), sCT(8-27), 11,18 Arg sCT(8-27), hAmylin(1-7)-11,18Arg-sCT(8-27)-Amylin(33-37), 14Glu11,38Arg-sCT(8-27), des-1Lys-h-amylin, 25Pro 26Val 28,29Pro-h-amylin, 18Arg 25,28Pro-h-amylin, des-1Lys 18Arg25,28Pro-h-amylin, 18Arg25,28,29Pro-h-amylin, des-1Lys 18Arg25,28,29Pro-h-amylin, des-1Lys25,28,29Pro-h-amylin, 14Pro 26Val 28,29Pro-h-amylin, 28Pro-h-amylin, 2-37h-amylin, 1Ala-h-amylin, 2Ala-h-amylin, 2,7Ala-h-amylin, 1Ser-h-amylin, 29Pro-h-amylin, 25,28Pro-h-amylin, des-1Lys 25,28Pro-h-amylin, 23Leu 25Pro 26Val 28,29Pro-h-amylin, 23Leu 25Pro 26Val 28Pro-h-amylin, des-1Lys 23Leu 25Pro 26Val 28Pro-h-amylin, 18Arg 23Leu 25Pro 26Val 28Pro-h-amylin, 18Arg 23Leu 25,28,29Pro-h-amylin, 18Arg 23Leu 25,28Pro-h-amylin, 17Ile 23Leu 25,28,29Pro-h-amylin, 17Ile 25,28,29Pro-h-amylin, des-1Lys 17Ile 23Leu 25,28,29Pro-h-amylin, 17Ile 18Arg 23Leu-h-amylin, 17Ile 18Arg 23Leu 26Val 29Pro-h-amylin, 17Ile 18Arg 23Leu 25Pro 26Val 28,29Pro-h-amylin, 13Thr 21His 23Leu 26Ala 28Leu 29Pro 31Asp-h-amylin, 12Thr 21Hid 23Leu 26Ala 29Pro 31Asp-h-amylin, des-1Lys 13Thr 21His 23Leu 26Ala 28Pro 31Asp-h-amylin, 13Thr 18Arg 21His 23Leu 26Ala 29Pro 31Asp-h-amylin, 13Thr 18Arg 21His 23Leu 28,29Pro 31Asp-h-amylin, and 13Thr 18Arg 21His 23Leu 25Pro 26Ala 28,29Pro 31Asp-h-amylin.

### Claim 37 (depends on 26)

The hybrid polypeptide of claim 26, wherein the C-terminus is amidated.

### Claim 38 (depends on 26)

The hybrid polypeptide of claim 26, wherein the first peptide hormone module is covalently linked through a linker to the second peptide hormone module.

### Claim 39 (depends on 38)

The hybrid polypeptide of claim 38, wherein the linker is chemically stable.

### Claim 40 (depends on 39)

The hybrid polypeptide of claim 39, wherein the linker comprises a moiety selected from the group consisting of an alkyl, a PEG, an amino acid, a polyaminoacid, a bifunctional linker, an aminocaproyl, a beta-alanyl, an 8-amino-3,6-dioxaoctanoyl, Lys, Glu, Gly, and Cys.

### Claim 41 (depends on 40)

The hybrid polypeptide of claim 40, wherein the linker comprises a moiety selected from the group consisting of poly-his, poly-arg, poly-lys, poly-ala, beta-alanyl beta-alanyl, Gly-Gly-Gly, or Gly-Lys-Arg.

### Claim 42 (depends on 40)

The hybrid polypeptide of claim 40, wherein the linker is 1 to 30 residues long, is 2 to 30 residues, or is 3 to 30 residues long.

### Claim 43 (depends on 42)

The hybrid polypeptide of claim 42, wherein the linker is 2, 3, 4, 5, 6, 7, 8, 9 or 10 residues long.

### Claim 44 (depends on 26)

The hybrid polypeptide of claim 26 wherein the hybrid is produced recombinantly.
